Sinopharm Group Co. Ltd. (the “Company”) released the principal unaudited financial data of its subsidiary, China National Medical Device Co., Ltd. (CNMDC), for the nine months ended 30 September 2025. According to the announcement, CNMDC recorded revenue of RMB54.69 billion, representing a year-on-year decrease of 2.41%. Operating profit stood at approximately RMB962.11 million, down 10.34% from the same period last year, while total comprehensive income attributable to owners of the parent company registered a 2.71% decline.

Net cash flow from operating activities improved significantly, reflecting a 49.55% reduction in net outflow compared with the corresponding period last year. During the reporting period, CNMDC reported total assets of RMB64.13 billion, a 4.01% increase compared with the beginning of the period. Meanwhile, total equity attributable to owners of the parent company rose by 3.86% to RMB8.19 billion.

The announcement provides shareholders and investors with the principal unaudited financial results of CNMDC, underscoring its performance in revenue, profitability, and financial position for the first three quarters of 2025.